Prosecution Insights
Prosecution Insights
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (75%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VANHORN, ABIGAIL LOUISE | 1 | 46.7% | +22.1% |
| WARD, PAUL V | 1 | 83.2% | -11.0% |
| KELLY-O'NEILL, YOLANDA LYNNETTE | 1 | 21.4% | +36.4% |
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 56.5% | +36.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18052505 | LIPID FORMULATIONS CONTAINING NUCLEIC ACIDS AND METHODS OF TREATMENT FOR CYSTIC FIBROSIS | WARD, PAUL V | 71d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17737690 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | KELLY-O'NEILL, YOLANDA LYNNETTE | 24d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001571 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | VANHORN, ABIGAIL LOUISE | 43d overdue |
| 17737690 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | KELLY-O'NEILL, YOLANDA LYNNETTE | 24d overdue |
| 17311271 | MODIFIED PROTEINS AND ASSOCIATED METHODS OF TREATMENT | DACE DENITO, ALEXANDRA GERALDINE | 70d |
| Art Unit | Apps |
|---|---|
| 1636 | 2 |
| 1622 | 1 |
| 1692 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18001571 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | VANHORN, ABIGAIL LOUISE | 1636 | Other | Non-Final OA | 43d overdue | Pending | Dec 12, 2022 |
| 18052505 | LIPID FORMULATIONS CONTAINING NUCLEIC ACIDS AND METHODS OF TREATMENT FOR CYSTIC FIBROSIS | WARD, PAUL V | 1622 | §103 | Non-Final OA | 71d overdue | Pending | Nov 03, 2022 |
| 17737690 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | KELLY-O'NEILL, YOLANDA LYNNETTE | 1692 | §103 | Non-Final OA | 24d overdue | Pending | May 05, 2022 |
| 17311271 | MODIFIED PROTEINS AND ASSOCIATED METHODS OF TREATMENT | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103 | Final Rejection | 70d | Pending | Jun 04, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial